Minerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer

32

WALTHAM, Mass.–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/cart?src=hash" target="_blank">#cart</a>–Minerva Biotechnologies reports the FDA has approved their IND application to conduct clinical trials in breast cancer with their MUC1* CAR T cells. http://www.businesswire.com/news/home/20190624005121/en/Minerva-Biotechnologies-Announces-FDA-Acceptance-IND-Application/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J